AACR WRAP UP CALL NICOLAI WAGTMANN APRIL 19 TH, 2016
|
|
- Oswin Harrell
- 5 years ago
- Views:
Transcription
1 AACR WRAP UP CALL NICOLAI WAGTMANN APRIL 19 TH, 216
2 FORWARD LOOKING STATEMENT This document has been prepared by Innate Pharma S.A. (the Company ) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company s actual results or financial condition to differ materially from those anticipated. Please refer to the risk factors outlined from time to time in the Company s regulatory filings or publications. This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of these data comes from external sources that are recognized in the field or from Company s estimates based on such sources. The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice. The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith. Please refer to the Document de Référence filed with the Autorité des marchés financiers ( AMF ) on March 12, 215, available on the AMF s website ( and on the Company s website ( Such documents may not be necessarily up to date. This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country. Page 2
3 INNATE PHARMA PIPELINE PROGRAM TARGET INDICATION STAGE Lirilumab Licensed to Bristol-Myers Squibb KIR2DL1,2,3 Acute Myeloid Leukemia - Single agent Solid and hematological tumors - Multiple combinations Phase II 6 Phase I & II trials Monalizumab Co-development with AstraZeneca NKG2A Solid and hematological tumors - Single agent and multiple combinations 5 Phase I/II trials IPH412 KIR3DL2 Cutaneous T-cell lymphomas Phase I IPH431 MICA Cancer Research IPH52 CD39 Cancer Research Discovery CD73 Cancer Research IPH33 TLR3 Inflammation Research TECHNOLOGY NK bispecific engagers COLLABORATIONS Sanofi Antibody Drug Conjugate (ADC) Page 3
4 AACR216 HIGHLIGHTS Broad pipeline of first-in-class checkpoint antibodies Monalizumab - durvalumab combo trial supported by data showing that addition of anti-nkg2a nearly doubled the frequency of complete tumor regressions compared to anti PD-1 alone First-in-class humanized pan-specific MICA/B acts by dual mode of action, exhibiting both ADCC and countering immuno-suppression First-in-class anti-cd39 mab targeting tumor microenvironment exhibits single-agent anti-tumor activity in mouse models New CD73 antibodies have compelling characteristics, strengthening Innate s positioning in targeting the tumor microenvironment Page 4
5 INNATE PHARMA PIPELINE PROGRAM TARGET INDICATION STAGE Lirilumab Licensed to Bristol-Myers Squibb KIR2DL1,2,3 Acute Myeloid Leukemia - Single agent Solid and hematological tumors - Multiple combinations Phase II 6 Phase I & II trials Monalizumab Co-development with AstraZeneca NKG2A Solid and hematological tumors - Single agent and multiple combinations 5 Phase I/II trials IPH412 KIR3DL2 Cutaneous T-cell lymphomas Phase I IPH431 MICA Cancer Research IPH52 CD39 Cancer Research Discovery CD73 Cancer Research IPH33 TLR3 Inflammation Research TECHNOLOGY NK bispecific engagers COLLABORATIONS Sanofi Antibody Drug Conjugate (ADC) Page 5
6 MONALIZUMAB FIRST-IN-CLASS ANTI-NKG2A MAB CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ASTRAZENECA
7 Combination MONALIZUMAB INITIAL CLINICAL DEVELOPMENT PLAN SETTING PATIENTS INDICATION STATUS LOCALIZATION Monotherapy Phase I/II 43 Head & Neck Neo-adjuvant setting Started Dec. 214 Europe Monotherapy Phase I/II 38 Ovarian cancer High grade platinum sensitive or resistant Started Sept. 215 Canada Ibrutinib Phase I/II Up to 45 Chronic Lymphocytic Leukemia Relapsed or refractory Started Oct. 215 US Cetuximab Phase I/II Up to 7 Head & Neck Relapsed or refractory Started Dec. 215 US and Europe Durvalumab (anti-pd-l1) Phase I with cohort expansion Up to 28 Solid tumors Started Feb. 216 US and Europe Page 7
8 MONALIZUMAB TARGETS NKG2A CHECKPOINT ON NK CELLS AND CD8 T CELLS NKG2A is an inhibitory receptor on tumor infiltrating CD8 T cells and NK cells NKG2A recognize HLA-E in humans and Qa-1 in mice NK cell Tumor cell CD8 T cell NK cell and T cell inhibition by NKG2A + Activation by NKG2A blockade Page 8
9 QA-1 b IS INDUCED ON A2 CELLS IN VITRO BY IFN-g AND IN VIVO AFTER ENGRAFTMENT IN MICE A Qa-1 b PD-L1 H-2K d Medium In vitro IFN-g B Ex vivo Qa1 and PD-L1 expression also upregulated on tumor-infiltrating macrophages and monocytes Page 9
10 NKG2A AND PD-1 EXPRESSION ON A2 TUMOR INFILTRATING NK AND CD8+ T CELLS IN UNTREATED MICE Spleen Tumor NK cells NKG2A - PD-1 - NKG2A - PD-1 + NKG2A + PD-1 - NKG2A + PD CD8 T cells Distribution of NKG2A and PD-1 receptors analyzed on day 22 (means of 6 mice/group) One third of tumor infiltrating PD-1+ CD8 T cells co-express NKG2A Page 1
11 T u m o r v o l u m e ( m m 3 ) ANTI-NKG2A: SINGLE-AGENT IN VIVO EFFICACY, DEPENDENT ON PRESENCE OF NK CELLS 4 3 PR: % CR: 18 % Isotype control 4 3 PR: % CR: 4 % Anti-NKG2A 4 3 PR: % CR: % Anti-NKG2A NK cell depleted Days Days Days Anti-NKG2A mab treatment induced NK cell-mediated anti-tumor efficacy in a prophylactic setting. Mice were randomized when tumor volumes 7 mm 3 (n=1-11/group) and treated 4 times (once a week) with IC, anti-nkg2a (2 µg, iv), or anti-asialo-gm1 (1 µl, ip) mabs. Tumor volume was measured twice a week. Individual tumor volumes of one experiment. Page 11
12 C D 8 + T l y m p h o c y t e s ( % ) THE FREQUENCY OF NKG2A+ CD8 T CELLS IS INCREASED IN MICE RESISTANT TO PD-1 PATHWAY BLOCKADE N K G 2 A + P D C D 8 + T c e l l s 1 5 * * * * s p l e e n * * * * t u m o r 1 * * * 5 I C A n t i - P D - 1 Mice treated with indicated mabs (2 µg, ip, 3 times every 3-4 days) after tumor engraftment were sacrificed on days 21 and 28. CD8 + T cells were characterized by flow cytometry. Means +/- SD of % NKG2A + PD-1 + CD8 + among CD8 + T cells. P<.5 (***), P<.5 (****). N=3-6. % NKG2A + NK cells among NK cells were not modified by anti-pd-1 treatment (data not shown). Page 12
13 T u m o r v o T l u m e o r ( m v o m l u 3 ) m e ( m m 3 ) T u m o r v o l u m e ( m m 3 ) T u m o r v o T l u m e o r ( m v m o l u 3 ) m e ( m m 3 ) S u r v i v a l S ( u % r ) v i v a l ( % ) A A A T u m o r v o l u m e ( m m 3 ) A T u m o r v o l u m e ( m m 3 ) COMBINED NKG2A AND PD-1 BLOCKADE INCREASES COMPLETE RESPONSE RATE AND SURVIVAL C o n t r o l 4 C o n t r o l 4 C o n t r o l 3 4 P R : 5 % 3 C R : 5 % 2 P R : 5 % 3 C R : 5 % 2 P R : 5 % 1 C R : 5 % D a y s P R : % C R : 3 7 % 2 P R : % P R : 5 % 3 C R : 3 7 % 2 C R : 2 P 5 R % : % 1 C R : 3 7 % A n t i - N K G 2 A 4 A n t i - N K G 2 A 4 A n t i - N K G 2 A 3 4 P R : 5 % 3 C R : 1 % 2 P R : 5 % 3 C R : 1 % 2 P R : 5 % 1 C R : 1 % D a y s D a y s D a y s D a y s D a y s A n t i - P D - 1 A n t i - N K G 2 A + A n t i - P D A n t i - P D - 1 C o n t r o l 4 A n t i - N K G 2 A + A n t i - P D - 1 A n t i - N K G 2 A A n t i - P D A n t i - N K G 2 A + A n t i - P D - 1 A n t i - N K G 2 A + A n t i - P D P R : 1 % C R : 6 3 % 3 2 P R : 1 % P R : 5 % 3 C R : 6 3 % 8 2 C R : P1 R %: 1 % 2 1 C R : 6 3 % D a y s D a y s D a y s D a y s * 8 6 * * 4 * * * * 6 * * 4 2 * * * * * * 4 * * * D a y s D a y s D a y s C o n t r o l A n t i - N K G 2 A A n t i - P D - 1 D a y s D a y s Mice were randomized when tumor volumes 7 mm (n=19-2 mice/group) and treated 3 times (every D a y s D a y s D a y s 3-4 days) with IC, anti-nkg2a (2 µg, iv), anti-pd-1 (2 µg, ip) or anti-nkg2a and anti-pd-1 mab. A: Pool of individual tumor volumes of two independent experiments. B: Kaplan-Meier survival. Log Rank test, P<.5 (*), P<.5 (**), P<.5 (***). A n t i - P D - 1 A n t i - N K G 2 A + A n t i - P D - 1 B B B B S u r v i v a l ( % ) S u r v i v a l ( % ) 2 C o n t r o l A n t i - N K G 2 A C o n t r o l A n t i - P D - 1 A n t i - N K G 2 A C o n t r o l A n t i - N K G 2 A + A n t i - P D - 1 A n t i - P D - 1 A n t i - N K G 2 A 1 A n t i - N K G 2 A + A n t i - P D - 1 A n t i - P D A n t i - N K G 2 A + A n t i - P D - 1 * * * * * * m 3 ) Page 13
14 CONCLUSIONS: IPH221 Preclinical mouse model presented at AACR strongly support the combination trial of monalizumab and durvalumab: > NKG2A ligand was not expressed on A2 cells at baseline, but induced on subcutaneous solid tumor cells similar to HLA-E overexpression on tumors vs normal cells in humans > NKG2A receptor expressed on over 5% of NK cells and induced on tumorinfiltrated CD8 T cells, particularly in mice resistant to anti-pd1 > Single-agent anti-nkg2a delayed tumor growth > Treatment with combination of NKG2A and PD-1 checkpoint inhibitors resulted in significantly enhanced anti-tumor responses. Nearly twice as many mice achieved complete tumor cell regression compared to treatment with PD-1 alone > Hence, NKG2A pathway may be a significant factor in adaptive resistance to PD-1 pathway blockade Page 14
15 INNATE PHARMA PIPELINE PROGRAM TARGET INDICATION STAGE Lirilumab Licensed to Bristol-Myers Squibb KIR2DL1,2,3 Acute Myeloid Leukemia - Single agent Solid and hematological tumors - Multiple combinations Phase II 6 Phase I & II trials Monalizumab Co-development with AstraZeneca NKG2A Solid and hematological tumors - Single agent and multiple combinations 5 Phase I/II trials IPH412 KIR3DL2 Cutaneous T-cell lymphomas Phase I IPH431 MICA Cancer Research IPH52 CD39 Cancer Research Discovery CD73 Cancer Research IPH33 TLR3 Inflammation Research TECHNOLOGY NK bispecific engagers COLLABORATIONS Sanofi Antibody Drug Conjugate (ADC) Page 15
16 IPH431: FIRST-IN-CLASS ANTI-MICA/B ANTIBODY MICA and MICB are polymorphic molecules often expressed on transformed and stressed cells MICA/B are ligands for NKG2D receptors on NK cells and CD8+ T cells. Kidney carcinoma CRC Endometrium Tumor localization Positive Cases (n=) Kidney 1% (2) Large intestine/sigmoid colon 1% (2) Endometrium 1% (1) Thyroid Gland Melanoma (lung metastasis) HCC Thyroid Gland 1% (1) Metastatic melanoma 9% (1) Liver 85% (2) Breast (TMA) 82% (28) Melanoma 71% (7) Lung (TMA) 62% (29) Chronic exposure to MICA/B down-regulates NKG2D receptors MICA/B can also be expressed on immunosuppressive macrophages Page 16
17 DUAL MECHANISM OF ACTION OF IPH431 PRESENTED AT AACR NK cell Tumor cell CD8 T cell Macrophage NK and T cell inhibition by chronic exposure to MICA/B + Dual mechanism of action: tumor antigen targeting and immunomodulation Page 17
18 IPH43: POTENT ADCC BY RESTING PRIMARY HUMAN NK CELLS A549 Raji-MICA* Binding % S p e c ific L y s is % S p e c ific L y s is M F I M F I Lysis A b. [µ g /m L ] A b. [µ g /m L ] IPH431 Isotype control Rituximab Cetuximab PBMC from healthy donors E/T = 2/1 Page 18
19 % C D N K c e lls % C D N K c e lls IPH431 OVERCOMES M2 MACROPHAGE-MEDIATED SUPPRESSION OF NK CELL ACTIVITY Isotype control IPH T u m o r c e lls M IC A * 1 M 1 m a c ro p h a g e s M 2 m a c ro p h a g e s Autologous macrophages and NK cells from healthy donors Page 19
20 P r o s ta te W e ig h t (g ) IPH43-moIgG2a CURES TRAMP-MICB MICE FROM PROSTATE CANCER Prostate weight (g) P= Isotype control IPH43-moIgG2a IPH43-moIgG2a is mousified IPH431 TRAMP/MICB mice described in Liu et al. In this model, male mice spontaneously develop prostate tumors expressing human MICB around 2 weeks of age Injections of mab i.v., twice a week starting from week 22 up to sacrifice at week 29 Page 2
21 IPH43-moIgG2a CURES TRAMP-MICB MICE FROM PROSTATE CANCER, RESTORING HISTOLOGY OF PROSTATE GLAND AND INDUCING NK CELL INFILTRATION Histology Isotype control (n=8) IPH43-moIgG2a (n=9) Normal/cured /8 4/9 (E) Well differentiated 5/8 (C) No NK infiltration 5/9 Localized or stabilized tumor (F) Poorly differentiated 3/8 (D) /9 NK infiltration IPH43-moIgG2a Isotype Control C. D. E. F. Page 21
22 CONCLUSIONS: IPH431 IPH431 is a humanized first-in-class pan allotype-specific anti-mica/b antibody which : > Efficiently mediates direct killing of tumor cells by ADCC > Overcomes suppressor macrophage-induced inhibition of NK cells > Inhibits MICA/B-induced NKG2D down-modulation > Demonstrates in vivo tumor efficacy in immuno-deficient mice > Mousified IPH43 cured TRAMP-MICB mice of prostate cancer Dual mechanism of action: Tumor antigen targeting and immunomodulation IND-enabling studies to start in 216 Page 22
23 INNATE PHARMA PIPELINE PROGRAM TARGET INDICATION STAGE Lirilumab Licensed to Bristol-Myers Squibb KIR2DL1,2,3 Acute Myeloid Leukemia - Single agent Solid and hematological tumors - Multiple combinations Phase II 6 Phase I & II trials Monalizumab Co-development with AstraZeneca NKG2A Solid and hematological tumors - Single agent and multiple combinations 5 Phase I/II trials IPH412 KIR3DL2 Cutaneous T-cell lymphomas Phase I IPH431 MICA Cancer Research IPH52 CD39 Cancer Research Discovery CD73 Cancer Research IPH33 TLR3 Inflammation Research TECHNOLOGY NK bispecific engagers COLLABORATIONS Sanofi Antibody Drug Conjugate (ADC) Page 23
24 THE ADENOSINE PATHWAY: ANTI-CD39 & ANTI-CD73 TARGETING THE TUMOR MICROENVIRONMENT T cell Other immune cell Tumor spreading NK cell Anti-CD39 Anti-CD39 Anti-CD73 Dendritic cell CD8 or CD4 T cell Tumor depletion CD39 and CD73 are enzymes expressed on regulatory T cells, immune cells and tumor cells > They promote immunosuppression by degrading adenosine triphosphate (ATP) into adenosine ATP : adenosine triphosphate AMP : adenosine monophosphate Page 24
25 IPH52: NOVEL, POTENT ANTI-CD39 ANTIBODY CD39 is expressed in several human cancers, including head & neck, lung, cervical, esophageal, sarcoma, liver, kidney, pancreatic, thyroid, endometrial tumors, as well as in lymphoma and melanoma Head & neck Squamous Cell Carcinoma Cervix Squamous cell carcinoma Liver Hepatocellular liver K Pancreas Adenocarcinoma Soft tissue Mucinous liposarcoma Lung AdenoK Esophagus Adenocarcinoma Kidney Clear Cell Carcinoma Thyroid Papillary carcinoma Uterus Endometrioid AdK IPH52 is a humanized anti-cd39 mab > Aims at preventing production of immunosuppressive Ado and promoting the accumulation of ATP in the tumor microenvironment > May stimulate anti-tumor immunity across a wide range of tumors Page 25
26 T u m o r v o lu m e (m m 3 ) P e r c e n t s u r v iv a l IPH52: NOVEL, POTENT ANTI-CD39 ANTIBODY VALIDATED IN PRECLINICAL MODELS IPH52 displays single agent activity Humanized mab inhibits tumor growth in xenogeneic tumor model T u m o r g r o w t h S u r v iv a l * * * * : p < D a y s d a y s H u a C D 3 9 H u IC Page 26
27 A M P (µ M ) HUMANIZED MAB INHIBITS CD39 ENZYME ACTIVITY IN MELANOMA TUMOR BIOPSIES H u m a n M e la n o m a B io p s ie s.8.6 P a tie n t1 P a tie n t2 P a tie n t B io p s y A T P B io p s y + A T P + H u IC + H u a C D 3 9 Efficacy of Hu acd39 to inhibit ATPase activity was evaluated on tumor biopsies, collected from 3 patients with metastatic melanoma, digested at 37 C with Collagenase and DNAse. Cells were further incubated with ATP at 4 C and AMP generated was quantified by Maldi Tof-MS. Page 27
28 POTENTIAL FOR COMBINATION WITH CANCER TREATMENTS CD39 disruption drives antitumor immune responses, either alone or in combination with PD-1 checkpoint blockers, ADCC antibodies and immunogenic chemotherapy, suggesting broad development potential Treatment with anti-pd1 and oxaliplatin in CD39 KO mice leads to 86% CR Tumor growth Survival WT mice CD39ko mice Page 28
29 CONCLUSIONS: IPH52 First-in-class humanized anti-cd39 mab with high affinity and specificity for CD39 blocks ATPase activity in vitro, both on tumor cells and immune cells In vivo, humanized anti-cd39 mab significantly inhibits CD39/CD73 positive tumor growth Broad development potential suggested by experiments in CD39 knock-out mice, including combination therapy with chemotherapy, ADCC-antibodies and/or immune checkpoint inhibitors IPH52 is currently in lead optimization Page 29
30 INNATE PHARMA PIPELINE PROGRAM TARGET INDICATION STAGE Lirilumab Licensed to Bristol-Myers Squibb KIR2DL1,2,3 Acute Myeloid Leukemia - Single agent Solid and hematological tumors - Multiple combinations Phase II 6 Phase I & II trials Monalizumab Co-development with AstraZeneca NKG2A Solid and hematological tumors - Single agent and multiple combinations 5 Phase I/II trials IPH412 KIR3DL2 Cutaneous T-cell lymphomas Phase I IPH431 MICA Cancer Research IPH52 CD39 Cancer Research Discovery CD73 Cancer Research IPH33 TLR3 Inflammation Research TECHNOLOGY NK bispecific engagers COLLABORATIONS Sanofi Antibody Drug Conjugate (ADC) Page 3
31 ANTI-CD73: NEW CHECKPOINT INHIBITOR PROGRAM TARGETING THE TUMOR MICROENVIRONMENT T cell Other immune cell Tumor spreading NK cell Anti-CD39 Anti-CD39 Anti-CD73 Dendritic cell CD8 or CD4 T cell Tumor depletion Targeting CD73 may block tumor cell metastasis by reducing the generation of immunosuppressive adenosine A panel of antibodies were discovered that inhibit CD73 function by different mechanisms, including the direct blocking of CD73 enzymatic activity or the down-modulation of membrane CD73 expression ATP : adenosine triphosphate AMP : adenosine monophosphate Page 31
32 M F I (x 1 5 ) M F I (x 1 5 ) M F I M F I ANTI-CD73 ANTIBODIES BIND WITH HIGH AFFINITY TO HUMAN AND CYNOMOLGUS CD73 MOLECULES A 4 C H O -h u C D C H O -c y n o C D C H O -m o C D 7 3 C m A b (n M ) m A b (n M ) m A b (n M ) B M D A -M B C y n o m -K m A b 1 m A b 2 m A b 3 m A b 4 T Y 2 3 C o n tro l KD (nm) Ka (1/Ms) Kd (1/s) mab E5 9.36E-5 mab E5 1.6E-4 mab E4 7.41E-5 mab E4 2.13E-4 m A b (n M ) m A b (n M ) Binding of anti-cd73 mabs was evaluated by flow cytometry A: on human, cynomolgus and mouse CD73- expressing CHO cell lines and B: on human (MDA-MB-231) and cynomolgus (Cynom-K1) cell lines that endogenously express CD73. C: Affinity of anti-cd73 mabs was measured by SPR. Page 32
33 P h o s p h a t e (% o f c e lls a lo n e ) P h o s p h a t e (% o f c e lls a lo n e ) P h o s p h a t e (% o f c e lls a lo n e ) MAB1 POTENTLY INHIBITS CELLULAR CD73 ENZYME ACTIVITY WITHOUT HOOK EFFECT A R e c o m b in a n t C D 7 3 B C e llu la r C D 7 3 a c tiv ity d o w n -m o d u la tio n E n z y m e A c tiv ity (% ) S to ic h io m e tric c o n d itio n s C D 7 3 e x p r e s s io n (% o f T ) m A b 1 m A b 2 m A b 3 m A b 4 C o n tro l C m A b (n M ) C e llu la r C D 7 3 a c tiv it y T im e (m in ) M D A -M B N C I-H A m A b (n M ) m A b (n M ) m A b (n M ) Recombinant CD73 was incubated with anti-cd73 mabs then with AMP (125 µm) and ATP (12.5 µm). A: AMP degradation was indirectly measured with Cell Titer Glo reagent. B: CD73 expression after MDA-MB-231 incubation with anti-cd73 mabs at 37 C was revealed by flow cytometry with non-competing anti-cd73 mabs. C: Human tumor cell lines were incubated with anti-cd73 mabs then with AMP (1 µm). Resulting phosphate was measured in the supernatant. Page 33
34 P r o lif (% o f c o n tro l) ANTI-CD73 ANTIBODIES EFFICIENTLY REVERSE AMP-MEDIATED T CELL SUPPRESSION Activated + AMP + mab1 Activated + AMP Activated Resting C T V o n to ta l T c e lls (M F I) C D 4 + T c e lls m A b (n M ) P r o lif (% o f c o n tro l) C D 8 + T c e lls m A b (n M ) m A b 1 m A b 2 m A b 3 m A b 4 C o n tro l Cell Trace Violet (CTV)-labelled lymphocytes were incubated with anti-cd73 mabs, anti-cd3/cd28- coated beads and AMP (8µM). Cell division was followed by flow cytometry. Page 34
35 CONCLUSIONS: CD73 We have discovered new original anti-cd73 checkpoint antibodies that block CD73 enzymatic activity and/or induce CD73 down-modulation The 4 mabs efficiently reverse AMP-dependent T cell suppression in vitro The mab that most potently inhibits CD73-mediated immune suppression (Ab1) is a strong blocker of CD73 enzyme activity The 4 mabs have distinct epitopes all located on the apex of the N-terminal domain of CD73 Antibodies displaying the most interesting features were humanized and further evaluation of their activity is ongoing Page 35
36 CONCLUSIONS Broad pipeline of first-in-class checkpoint antibodies Monalizumab - durvalumab combo trial supported by data showing that addition of anti-nkg2a nearly doubled the frequency of complete tumor regressions compared to anti PD-1 alone First-in-class humanized pan-specific MICA/B acts by dual mode of action, exhibiting both ADCC and countering immuno-suppression First-in-class anti-cd39 mab targeting tumor microenvironment exhibits single-agent anti-tumor activity in mouse models New CD73 antibodies have compelling characteristics, strengthening Innate s positioning in targeting the tumor microenvironment Page 36
37 OUR RESEARCH AMBITIONS Strengthening our preclinical pipeline Growing capabilities Expanding into tumor microenvironment Harnessing our innate immunity focus and expertise Page 37
38 WHERE TO SEE US IN Q2 CIMT: Mechanisms of Efficacy in Cancer Immunotherapy Mainz - Germany May 1, 216 to May 12, 216 Innate Pharma Research Day New York, USA May 16, 216 ASCO Annual Meeting 216 Chicago, USA June 3, 216 to June 7, 216 Citi Swiss Healthcare Investor Day Zurich, Switzerland May 19, 216 Goldman Sachs 37th Annual Global Healthcare Conference Rancho Palos Verdes, USA June 7 to June 9, 216 Bryan Garnier 1st Oncology Day Paris, France June 17, 216 Société Générale CIB Healthcare & Biotechnology Conference Paris, France June 28, 216 For more events, visit our website or and our booth #264 at AACR meeting Page 38
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationCOMPANY PRESENTATION. Hervé Brailly, CEO Jefferies 2014 Healthcare Conference. Page 1
COMPANY PRESENTATION Hervé Brailly, CEO Jefferies 2014 Healthcare Conference Page 1 Forward Looking Statement This document has been prepared by Innate Pharma S.A. (the Company ) solely for the purposes
More informationTHE INNATE IMMUNITY COMPANY
THE INNATE IMMUNITY COMPANY NEXT GENERATION IMMUNOTHERAPIES: NK CELLS AND OTHER TARGETS STEPHANIE CORNEN 5TH IMMUNOTHERAPY OF CANCER CONFERENCE (ITOC5) MARCH 2018 Page 2 FORWARD LOOKING STATEMENT This
More informationANTI-C5AR ACQUISITION
KIR2DL1,2,3 NKG2A NKP46 KIR3DL2 MICA/B CD73 CD39 ANTIC5AR ACQUISITION JUNE 2017 NOVEL CHECKPOINTS IN IMMUNOONCOLOGY Page 2 FORWARD LOOKING STATEMENT This document has been prepared by Innate Pharma S.A.
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationCiti Global Healthcare Conference
Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24, 2014 1 Forward-Looking Information During this meeting, we will make statements about the Company s
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationBreakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015
Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation June 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationLAG-3: Validation Of Next Generation Checkpoint Pathways
LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationReprogramming Tumor Associated Dendritic Cells for Immunotherapy
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy Edgar Engleman, M.D. Professor of Pathology and Medicine Stanford University Disclosures: Founder of Dendreon, a biotechnology company that
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationCOMPANY PRESENTATION. January 2019
COMPANY PRESENTATION January 2019 1 FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationPersonalized Cancer Neoantigen Vaccines
Personalized Cancer Neoantigen Vaccines Turning the Immune System Against Your own Unique Tumour-Specific Antigens 3 rd Annual Advances in Immuno-Oncology Congress London, May 24, 2018 Agnete Fredriksen,
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationCompany Presentation. September 2018 NASDAQ: VBLT
Company Presentation September 2018 NASDAQ: VBLT Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vascular Biogenics
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationEnhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine
SMi Immuno-Oncology, London Loui Madakamutil, Ph. D Vice President, Head for Discovery Enhanced cancer vaccine effectiveness with NKTR-214, a CD122 biased cytokine Sept 26-27 2018 Nektar Therapeutics San
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationMerus. Corporate Presentation. November 15, 2018
Merus Corporate Presentation November 15, 2018 Disclaimer This presentation (including any oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationTMAC Affimer Drug Conjugates
TMAC Affimer Drug Conjugates A novel and proprietary class of immuno-oncology active, dual mode of action drug conjugates PRS 001 Immune-checkpoint Therapies: Improving Patient Response Rates Despite great
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationCB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response
CB-1158 Inhibits the Immuno-oncology Target Arginase and Causes an Immune Mediated Anti-Tumor Response Francesco Parlati, Ph.D. Calithera Biosciences South San Francisco, CA Arginine Depletion by Arginase
More informationThe Tumor Microenvironment Company
The Tumor Microenvironment Company June 2018 Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationJP Morgan Healthcare Conference. Howard Robin President & CEO January 9, 2018
JP Morgan Healthcare Conference Howard Robin President & CEO January 9, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start
More informationAXL inhibition to prolong life
AXL inhibition to prolong life First-in-class medicines to treat aggressive cancers Jefferies London Healthcare Conference November 15-16 th 2017 Richard Godfrey, CEO 1 Disclaimer Certain statements contained
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationOMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors
OMP-305B83: A Novel, Potent DLL4 & VEGF Targeting Bispecific Antibody for the Treatment Of Solid Tumors Jakob Dupont MD MA CMO, SVP: OncoMed Pharmaceuticals Adjunct Clinical Faculty: Stanford University
More informationNKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationDual-targeting anti- CD47 bispecific antibodies: Safely provoking macrophages to feast NALM-6 tumor cells (B-ALL) Human macrophages
Dual-targeting anti- CD47 bispecific antibodies: Safely provoking macrophages to feast Krzysztof Masternak, PhD, Head of Biology 1 2 nd Biologics & BOARD Biosimilars MEETING Congress MARCH 2012 NALM-6
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationPhase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell
Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationCelldex Provides Corporate Update and Reports First Quarter 2018 Results
May 10, 2018 Celldex Provides Corporate Update and Reports First Quarter 2018 Results HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationImmuno-Oncology: Perspectives on Current Therapies & Future Developments
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/immuno-oncology-perspectives-currenttherapies-future-developments/9502/
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationSupplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/8/352/352ra110/dc1 Supplementary Materials for Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More information(212) Investors Contact: Ryan Crowe (212)
For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationJefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationCelyad s CAR-T NKR-2 Program. Conference Call Presentation Wednesday, December 7 th :00pm CET / 8:00am EST
Celyad s CAR-T NKR-2 Program Conference Call Presentation Wednesday, December 7 th 2016 2:00pm CET / 8:00am EST Forward Looking Statements In addition to historical facts or statements of current condition,
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationA NEW FRONTIER IN IMMUNO-ONCOLOGY
A NEW FRONTIER IN IMMUNO-ONCOLOGY Proactive One2One Forum London, March 8 th 2018 Dr Richard Goodfellow LSE: SCLP.L CLINICAL STAGE IMMUNO-ONCOLOGY COMPANY Scancell is developing innovative immunotherapies
More informationCAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris
CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationBiogen Idec Oncology Pipeline. Greg Reyes, MD, PhD SVP, Oncology Research & Development
Biogen Idec Oncology Pipeline Greg Reyes, MD, PhD SVP, Oncology Research & Development March 25, 2009 Biogen Idec Strategy in Lymphoma / Leukemia CLL RITUXAN NHL FC-RITUXAN GA101 RITUXAN-CVP RITUXAN-CHOP
More informationTumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationDisclosures. Speakers Bureau. Clinical Trial Research Funding
Interim Results of an Ongoing Phase 1, Dose Escalation Study of MGA271 (Enoblituzumab), an Fc optimized Humanized Anti B7 H3 Monoclonal Antibody, in Patients with Advanced Solid Cancer Powderly J a, Cote
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More information